Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 39

1.

Unified theory of Alzheimer's disease (UTAD): implications for prevention and curative therapy.

Nehls M.

J Mol Psychiatry. 2016 Jul 15;4:3. doi: 10.1186/s40303-016-0018-8. eCollection 2016. Review.

2.

The Therapeutic Potential of Rosemary (Rosmarinus officinalis) Diterpenes for Alzheimer's Disease.

Habtemariam S.

Evid Based Complement Alternat Med. 2016;2016:2680409. doi: 10.1155/2016/2680409. Epub 2016 Jan 28. Review.

3.

Hippocampal Non-Theta-Contingent Eyeblink Classical Conditioning: A Model System for Neurobiological Dysfunction.

Cicchese JJ, Berry SD.

Front Psychiatry. 2016 Feb 12;7:1. doi: 10.3389/fpsyt.2016.00001. eCollection 2016. Review.

4.

Clinical and research value of the new diagnostic criteria for Alzheimer's disease.

Wei C.

Shanghai Arch Psychiatry. 2015 Apr 25;27(2):124-5. doi: 10.11919/j.issn.1002-0829.215046.

5.

Protective effects of low-intensity pulsed ultrasound on aluminum-induced cerebral damage in Alzheimer's disease rat model.

Lin WT, Chen RC, Lu WW, Liu SH, Yang FY.

Sci Rep. 2015 Apr 15;5:9671. doi: 10.1038/srep09671.

6.

Would older adults with mild cognitive impairment adhere to and benefit from a structured lifestyle activity intervention to enhance cognition?: a cluster randomized controlled trial.

Lam LC, Chan WC, Leung T, Fung AW, Leung EM.

PLoS One. 2015 Mar 31;10(3):e0118173. doi: 10.1371/journal.pone.0118173. eCollection 2015.

7.

Roles of resveratrol and other grape-derived polyphenols in Alzheimer's disease prevention and treatment.

Pasinetti GM, Wang J, Ho L, Zhao W, Dubner L.

Biochim Biophys Acta. 2015 Jun;1852(6):1202-8. doi: 10.1016/j.bbadis.2014.10.006. Epub 2014 Oct 12. Review.

8.

Effects of non-pharmacological or pharmacological interventions on cognition and brain plasticity of aging individuals.

Pieramico V, Esposito R, Cesinaro S, Frazzini V, Sensi SL.

Front Syst Neurosci. 2014 Sep 2;8:153. doi: 10.3389/fnsys.2014.00153. eCollection 2014. Review.

9.

Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014.

Schneider LS, Mangialasche F, Andreasen N, Feldman H, Giacobini E, Jones R, Mantua V, Mecocci P, Pani L, Winblad B, Kivipelto M.

J Intern Med. 2014 Mar;275(3):251-83. doi: 10.1111/joim.12191. Review.

10.

Latrepirdine: molecular mechanisms underlying potential therapeutic roles in Alzheimer's and other neurodegenerative diseases.

Bharadwaj PR, Bates KA, Porter T, Teimouri E, Perry G, Steele JW, Gandy S, Groth D, Martins RN, Verdile G.

Transl Psychiatry. 2013 Dec 3;3:e332. doi: 10.1038/tp.2013.97. Review.

11.

Treatment for mild cognitive impairment: systematic review.

Cooper C, Li R, Lyketsos C, Livingston G.

Br J Psychiatry. 2013 Sep;203(3):255-64. doi: 10.1192/bjp.bp.113.127811. Review. Erratum in: Br J Psychiatry. 2014 Jan;204(1):81.

12.

The impact of AD drug treatments on event-related potentials as markers of disease conversion.

Chapman RM, Porsteinsson AP, Gardner MN, Mapstone M, McCrary JW, Sandoval TC, Guillily MD, Reilly LA, DeGrush E.

Curr Alzheimer Res. 2013 Sep;10(7):732-41.

13.

Potential therapeutic effect of nanobased formulation of rivastigmine on rat model of Alzheimer's disease.

Ismail MF, Elmeshad AN, Salem NA.

Int J Nanomedicine. 2013;8:393-406. doi: 10.2147/IJN.S39232. Epub 2013 Jan 23.

14.

Fluid biomarkers in Alzheimer disease.

Blennow K, Zetterberg H, Fagan AM.

Cold Spring Harb Perspect Med. 2012 Sep 1;2(9):a006221. doi: 10.1101/cshperspect.a006221. Review.

15.

Effect of toki-shakuyaku-san on regional cerebral blood flow in patients with mild cognitive impairment and Alzheimer's disease.

Matsuoka T, Narumoto J, Shibata K, Okamura A, Taniguchi S, Kitabayashi Y, Fukui K.

Evid Based Complement Alternat Med. 2012;2012:245091. doi: 10.1155/2012/245091. Epub 2012 Feb 12.

16.

Learning, attentional control, and action video games.

Green CS, Bavelier D.

Curr Biol. 2012 Mar 20;22(6):R197-206. doi: 10.1016/j.cub.2012.02.012. Review.

17.

Prevalence, distribution, and impact of mild cognitive impairment in Latin America, China, and India: a 10/66 population-based study.

Sosa AL, Albanese E, Stephan BC, Dewey M, Acosta D, Ferri CP, Guerra M, Huang Y, Jacob KS, Jiménez-Velázquez IZ, Rodriguez JJ, Salas A, Williams J, Acosta I, González-Viruet M, Hernandez MA, Shuran L, Prince MJ, Stewart R.

PLoS Med. 2012 Feb;9(2):e1001170. doi: 10.1371/journal.pmed.1001170. Epub 2012 Feb 7.

18.

Informant-reported cognitive symptoms that predict amnestic mild cognitive impairment.

Malek-Ahmadi M, Davis K, Belden CM, Jacobson S, Sabbagh MN.

BMC Geriatr. 2012 Feb 3;12:3. doi: 10.1186/1471-2318-12-3.

19.

An update on the diagnosis and management of dementing conditions.

Maalouf M, Ringman JM, Shi J.

Rev Neurol Dis. 2011;8(3-4):e68-87. Review.

20.

Supplemental Content

Support Center